Journal
EMERGING MICROBES & INFECTIONS
Volume 9, Issue 1, Pages 194-206Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1713707
Keywords
HIV-1; broadly neutralizing antibodies (bNAbs); efficacies; challenges; opportunities
Categories
Funding
- National Natural Science Foundation of China [31670945]
- Yunan Province Major Project for Science and Technology of China [2018IA044]
- CAMS Innovation Fund for Medical Sciences [2017-12M-2-006, CAMS-I2M-1-014]
- PUMC Innovation Fund for postgraduates [2017-1002-1-18]
- National megaproject on key infectious diseases [2017ZX10202102-004-003]
Ask authors/readers for more resources
Combination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advancing into clinical trials have shown certain efficacies in infected individuals. In addition, bNAbs have the potential to kill HIV-1-infected cells and to affect the course of HIV-1 infection by directly engaging host immunity. Nonetheless, challenges accompany the use of bNAbs, including transient suppression of viraemia, frequent emergence of resistant viruses in rebound viraemia, suboptimal efficacy in virus cell-to-cell transmission, and unclear effects on the cell-associated HIV-1 reservoir. In this review, we discuss opportunities and potential strategies to address current challenges to promote the future use of immunotherapy regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available